ADMA Quote, Financials, Valuation and Earnings

Blueprint Medicines has a net margin of 23.44% compared to ADMA Biologics's net margin of 0.33%. ADMA Biologics's return on equity of 79.75% beat Blueprint Medicines's return on equity of -49.13%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 56.11%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -1.08%. Given that ADMA Biologics has higher upside potential than Blueprint Medicines, analysts believe ADMA Biologics is more attractive than Blueprint Medicines.

ADMA Biologics has a beta of 0.466, which suggesting that the stock is 53.408% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.841, suggesting its less volatile than the S&P 500 by 15.895%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. ADMA Biologics's net income of $26.9M is higher than Blueprint Medicines's net income of $496K. Notably, ADMA Biologics's price-to-earnings ratio is 22.22x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.07x versus 14.62x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of 23.44% compared to ADMA Biologics's net margin of 40.12%. ADMA Biologics's return on equity of 79.75% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 56.11%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.29 which suggests that it could grow by 44.85%. Given that ADMA Biologics has higher upside potential than Catalyst Pharmaceuticals, analysts believe ADMA Biologics is more attractive than Catalyst Pharmaceuticals.

ADMA Biologics has a beta of 0.466, which suggesting that the stock is 53.408% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.922%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. ADMA Biologics's net income of $26.9M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, ADMA Biologics's price-to-earnings ratio is 22.22x while Catalyst Pharmaceuticals's PE ratio is 15.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.07x versus 5.57x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Geron has a net margin of 23.44% compared to ADMA Biologics's net margin of -50.09%. ADMA Biologics's return on equity of 79.75% beat Geron's return on equity of -46.58%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 56.11%. On the other hand Geron has an analysts' consensus of $3.69 which suggests that it could grow by 137.9%. Given that Geron has higher upside potential than ADMA Biologics, analysts believe Geron is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.466, which suggesting that the stock is 53.408% less volatile than S&P 500. In comparison Geron has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.798%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are larger than Geron quarterly revenues of $39.6M. ADMA Biologics's net income of $26.9M is higher than Geron's net income of -$19.8M. Notably, ADMA Biologics's price-to-earnings ratio is 22.22x while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.07x versus 8.82x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of 23.44% compared to ADMA Biologics's net margin of -151.35%. ADMA Biologics's return on equity of 79.75% beat Rhythm Pharmaceuticals's return on equity of -116.92%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 56.11%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $83.42 which suggests that it could grow by 33.7%. Given that ADMA Biologics has higher upside potential than Rhythm Pharmaceuticals, analysts believe ADMA Biologics is more attractive than Rhythm Pharmaceuticals.

ADMA Biologics has a beta of 0.466, which suggesting that the stock is 53.408% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.301, suggesting its more volatile than the S&P 500 by 130.127%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $32.7M. ADMA Biologics's net income of $26.9M is higher than Rhythm Pharmaceuticals's net income of -$49.5M. Notably, ADMA Biologics's price-to-earnings ratio is 22.22x while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.07x versus 28.14x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.